GPP has no known cause but,
Currently, only SPEVIGO is approved in the United States. In contrast, Japan has a broader therapeutic landscape for Generalized Pustular Psoriasis, including supportive treatment regimens.
To maintain competitiveness in the Generalised Pustular Psoriasis (GPP) domain in the short to mid-long term, it is important to understand the complete GPP development pipeline. This involves staying updated on the evolving treatment landscape, upcoming advancements, and competitive strategies.
Figure 1 GPP development pipeline
Profiles of key stakeholders advancing Generalised Pustular Psoriasis (GPP) solutions offer valuable insights into their financial standing, product portfolios, and recent innovations within the sector.
Figure 2 Company Profile
This report examines patents associated with Generalised Pustular Psoriasis (GPP), highlighting notable innovations and emphasizing opportunities for improvement or collaboration within the field.
Figure 3 Patent Legal status of Standard current assignees
Figure 4 Region-wise patent count of standard current assignees
This report forecasts upcoming advancements, outlines pathways for expansion, and provides critical insights into market dynamics, including scale, revenue forecasts, and growth opportunities.
Figure 5 Country-wise Forecast
The competitive landscape section offers a comprehensive analysis of key market players in the Generalised Pustular Psoriasis (GPP) domain, including their market shares and concise profiles detailing strengths, weaknesses, and strategies. Additionally, it provides competitive benchmarking services for comparative performance insights and industry standards.
Figure 6 Scoring of key players in GPP domain
Explore cutting-edge and latest diagnostic and treatment solutions to address the complexities of GPP, enabling precise disease management and treatment planning to improve patient outcomes.
Investigate emerging therapies targeting specific molecular abnormalities in GPP, revolutionizing treatment paradigms and offering new hope for enhanced quality of life and functional outcomes for patients.
Assess worldwide trends and investment opportunities in GPP management, providing valuable insights into the evolving landscape of disease management, fostering enhanced diagnostic precision, and treatment efficacy on a global scale.
Highlighting key partnerships propelling innovation and advancements in GPP management strategies, promoting collaborative efforts aimed at enhancing patient care and improving the quality of life for individuals affected by the disease.
Explore cutting-edge diagnostic techniques and patented advancements enhancing precision in GPP diagnosis and treatment. These breakthroughs aim to transform patient care and improve management strategies, offering new approaches for early detection and personalized treatment.
Identify growth areas and obstacles in GPP diagnosis, streamlining processes for affected individuals and enhancing healthcare delivery. Recognize opportunities for advancing diagnostic and treatment approaches to address challenges associated with this complex skin disease, optimizing patient outcomes and reducing healthcare burdens.
Stay updated on evolving trends in GPP diagnosis, including advancements in imaging modalities and non-invasive diagnostic tools. These developments shape the diagnostic landscape and expand treatment options for patients, improving early detection and intervention.
Evaluate recent breakthroughs broadening treatment options and improving accuracy in GPP diagnosis. From novel drug therapies to minimally invasive procedures, these advancements hold promise for enhancing patient outcomes and quality of life, driving progress in GPP management.
Stay abreast about ongoing clinical trials contributing to enhanced accessibility and precision in therapeutic interventions for GPP. These trials drive therapeutic advancements and improve patient care by evaluating the efficacy and safety of new treatments and technologies.
Understand the leading companies and research institutions pioneering innovation in GPP diagnosis and treatment. Their efforts facilitate advancements in managing the complexities of this challenging skin disorder, shaping the future of GPP care through collaborative research and development initiatives.
In order to give the most precise estimations and forecasts, Wissen Research uses an extensive and iterative research approach that is focused on reducing deviation. The company blends top-down and bottom-up methodologies for market segmentation and quantitative estimation. In addition, data triangulation, which examines the market from three separate angles, is a recurrent topic present in all of our research studies. Important components of the approach used for all of our studies include the following:
Preliminary data mining
On a wide scale, unprocessed market data is collected. Continuous data filtering makes sure that only verified and authenticated sources are taken into account. Additionally, data is extracted from a wide range of reports in our repository and from a number of reputable premium databases. We gather information from raw material suppliers, distributors, and purchasers to help with this since understanding the entire value chain is crucial for a thorough understanding of the market.
Surveys, technical symposia, and trade magazines are used to gather information on technical concerns and trends. Technical information focusing on white space and freedom of movement is also obtained from an intellectual property standpoint. Additionally, information on the industry’s drivers, constraints, and pricing patterns is obtained. As a result, a variety of original data are included in the material that is then cross-validated and certified with published sources.
Statistical model
We use simulation models to generate our market projections and estimates. Every study receives a special model that is tailored to it. Data for market dynamics, the technology environment, application development, and pricing patterns are gathered and supplied into the model all at once for analysis. The relative relevance of these factors is investigated, and their impact on the forecast period is assessed, using correlation, regression, and time series analysis. The process of market forecasting combines technological analysis with economic strategies, practical business acumen, and subject expertise.
Econometric models are frequently used for short-term forecasting, but technology market models are typically employed for long-term forecasting. These are based on a confluence of the business environment, regulatory environment, economic projection, and technical landscape. In order to develop global estimates, it is preferable to estimate markets from the bottom up by integrating data from key regional markets. This is required to ensure accuracy and a complete comprehension of the subject. Among the variables taken into account for forecasting are:
Regulations and anticipated developments
We give these criteria weights and use weighted average analysis to assess their market influence in order to calculate the anticipated market growth rate.
Data Collection Matrix:
Primary research | Secondary research |
· Manufacturers · Technology distributors and wholesalers · End-user surveys · Consumer surveys | · Company reports and publications · Government publications · Independent investigations · Economic and demographic data · Online searches · Research reviews · Reference customers |
1. Introduction
1.1. Overview of GPP
1.2. Causes and Risk Factors
1.3. Symptoms and Diagnosis
1.4. Epidemiology, Prevalence and Incidence
2. Treatment Approaches
2.1. Current Treatment Approaches
2.2. Research on New Treatment Options
2.3. Our Report Focus
3. Market Insight
3.1. Market Trends in GPP
3.2. Market Drivers and Challenges
3.3. Recent Developments
3.3.1. Mergers and Acquisitions
3.3.2. Collaborations, Partnerships, and Agreements
3.3.3. Product Launches and Approvals
4. Patent Analysis
4.1. Top Assignees in GPP Technology
4.2. Geography Focus of Top Assignees
4.3. Legal Status of GPP Patents
4.4. Assignee Segmentation
4.5. Network Analysis of Top Collaborating Entities in GPP Patent Applications
4.6. Technology Evolution in GPP
4.7. Key Patents in GPP
4.8. Patent Trends and Innovations
4.9. Key Players and Patent Portfolio Analysis
5. Clinical Trial Analysis
5.1. Overview of GPP Clinical Trials
5.2. Analysis by Trial Registration Year
5.3. Analysis by Phase of Development
5.4. Analysis by Number of Patients Enrolled
5.5. Analysis by Status of Trial
5.6. Analysis by Study Design
5.7. Analysis by Intervention Type
5.8. Analysis by Geography
5.9. Analysis by Key Sponsors/Collaborators
6. Market Forecast (2024-2034)
6.1. Methodology
6.2. Assumptions
6.3. Projected Growth of GPP Market (2024-2034)
6.3.1. Global GPP Market (2024-2034)
6.3.1.1. By Therapy
6.3.1.1.1. Monoclonal Antibodies
6.3.1.1.2. Biologics and Non-biologics
6.3.1.1.3. Phototherapy
6.3.1.1.4. Others
6.3.1.2. By Route of Administration
6.3.1.2.1. Topical
6.3.1.2.2. Intravenous
6.3.1.2.3. Others
6.3.2. Market Value Forecast in North America, Europe, and Asia Pacific (2024-2034)
6.3.2.1. By Therapy
6.3.2.1.1. Monoclonal Antibodies
6.3.2.1.2. Biologics and Non-biologics
6.3.2.1.3. Phototherapy
6.3.2.1.4. Others
6.3.2.2. By Route of Administration
6.3.2.2.1. Topical
6.3.2.2.2. Intravenous
6.3.2.2.3. Others
7. Competitive Landscape
7.1. Benchmarking Parameters
7.2. Scoring of Different Companies
7.3. Top Company Profiles
7.3.1. AnaptysBio
7.3.2. Takeda
7.3.3. Johnson & Johnson
7.3.4. Inmagene Biopharmaceuticals
7.3.5. Boehringer Ingelheim
7.3.6. AbbVie
7.3.7. Amgen
7.3.8. UCB Biopharma
7.3.9. Company 9
7.3.10. Company 10
7.3.11. Others
7.4. Product Portfolio Analysis
7.5. Recent Developments and Strategies
8. Future Outlook and Market Opportunities
8.1. Technological Advancements in GPP Research
8.2. Unmet Needs and Potential Market Gaps
9. Conclusion
10. Appendix
10.1. Glossary of Terms
10.2. List of Abbreviations
S.no | Key Highlights of Report | |
1. | Patent Analysis | · Top Assignee · Geography focus of top Assignees · Assignee Segmentation · Technology Evolution · Key Patents · Application and Issued Trend · Key technology |
2. | Market Analysis | · Current Treatment Options · Emerging Therapies and Research Developments (by product analysis and scientific analysis) · Strategic activities · Therapeutic activity of drugs · Company portfolio · Detailed profiles of the key players that are engaged in the development of approved drugs |
3. | Clinical Trials | · Analysis of clinical trial through graphical representation · Coverage of treatments from pre-clinical phases till commercialization (also including terminated and completed studies) |
4. | Forecast | · Detailed comprehension of the historic, current and forecasted trend of market by analysis of impact of these treatments on the market |
5. | Opportunity Analysis | · Technology evolution based on problem solution · Potential licensees · Treatment trends · Unmet needs · SWOT · Drivers and barriers |
6. | KOLs | · A detailed analysis and identification of the Key Opinion Leaders (KOLs), shortlisted based on their contributions |
LIST OF FIGURES
Figure number | Description |
Figure 1 | Terminology of Generalised Pustular Psoriasis (GPP) Over The Years |
Figure 2 | Generalised Pustular Psoriasis (GPP)– History and Present |
Figure 3 | Projection of Generalised Pustular Psoriasis (GPP) till 2034 in different geographies |
Figure 4 | Technology Categorization For Generalised Pustular Psoriasis (GPP) therapies |
Figure 5 | Recent Technology Trends in Generalised Pustular Psoriasis (GPP) therapies |
Figure 6 | Technology Evolution in Generalised Pustular Psoriasis (GPP) therapies |
Figure 7 | Geographical Distribution of Patents of Top Assignees |
Figure 8 | Assignee Segmentation (Companies) |
Figure 9 | Assignee Segmentation (Educational Establishment) |
Figure 10 | Patent Based Key Insights Of xx |
Figure 11 | Patent Based Key insights of xx |
Figure 12 | Patent Based Key insights of xx |
Figure 13 | Geographic Distribution of the Universities/Research Organizations Filling Patents On Various Technology advancements |
Figure 14 | Key Summary Regarding the Patent Filing On Generalised Pustular Psoriasis (GPP) |
Figure 15 | Product Pipeline of Different therapeutic approaches with Companies Name |
Figure 16 | Portfolio for Government Approved GPP medications |
Figure 17 | Key Growth Drivers for Generalised Pustular Psoriasis (GPP) Market |
Figure 18 | Restraints for Generalised Pustular Psoriasis (GPP) Market |
Figure 19 | xx Portfolio (Top Player) |
Figure 20 | xx Portfolio (Top Player) |
Figure 21 | xx Portfolio (Top Player) |
Figure 23 | xx Portfolio (Top Player) |
Figure 24 | xx Portfolio (Top Player) |
Figure 25 | xx Portfolio (Start-up) |
Figure 26 | xx Portfolio (Start-up) |
Figure 27 | xx Portfolio (Start-up) |
Figure 28 | Strategic Activities Including Collaboration, Partnerships and Acquisitions |
Figure 29 | Research Methodology for Patent, Selection and Analysis |
LIST OF GRAPHS
Graph number |
Description |
Graph 1 | Problem Solution Analysis |
Graph 2 | Top Assignees in Generalised Pustular Psoriasis (GPP) treatment therapy |
Graph 3 | Technology Focus of Top Assignees (IPC-CPC Classes) |
Graph 4 | Top Countries of Origin of Patents |
Graph 5 | New entrants in GPP field |
Graph 7 | Legal Status |
Graph 8 | Most Cited Patents |
Graph 9 | Patents with Largest Invention Families |
Graph 10 | Most Claim-Heavy Patents |
Graph 11 | Filing Trends |
Graph 12 | Weighted Scores for Top xx Players According to Benchmarking Criteria |
Graph 13 | Generalised Pustular Psoriasis (GPP) (CAGR: 2024-2034) |
Graph 14 | Generalised Pustular Psoriasis (GPP) Market Share: Distribution by Key Geographical Area, 2024-2034 |
LIST OF TABLES
Table number | Description |
Table 1 | Parameters included and excluded for conducting the analysis |
Table 2 | Technology Classes with Definitions |
Table 3 | Patent Litigation |
Table 4 | Highest Market Valued Patents |
Table 5 | SWOT Analysis of Top 3 Players |
Table 6 | Parameters and their score for Benchmarking |
Table 7 | Weighted scores for top 5 players according to benchmarking criteria |
